As filed with the U.S. Securities and Exchange Commission on December 17, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INVO FERTILITY, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Commission Nevada 001-39701 20-4036208 (I.R.S. Employer Identification Number) 5582 Broadcast Court Sarasota, Florida, 34240 (978) 878 ...

Core Viewpoint - INVO Fertility, Inc. has announced a private placement offering to raise approximately $4.0 million through the sale of common stock and warrants, aimed at expanding its operations in the fertility market [1][2]. Group 1: Offering Details - The company will sell 2,366,864 shares of common stock and warrants to purchase up to 4,733,728 additional shares, with a combined effective offering price of $1.69 per share [1]. - The warrants will have an exercise price of $1.69 per share, exercisable upon shareholder approval, and will expire five years from the date of such approval [1]. - The offering is expected to close on or about December 3, 2025, pending customary closing conditions [2]. Group 2: Financial Implications - Gross proceeds from the offering are estimated to be approximately $4.0 million before deducting fees and expenses related to the placement [2]. - Maxim Group LLC is acting as the sole placement agent for this offering [2]. Group 3: Company Overview - INVO Fertility is focused on expanding assisted reproductive technology (ART) care, operating fertility clinics, and distributing its proprietary INVOcell technology [5]. - The company operates two INVO Centers and one IVF clinic in the United States, offering the intravaginal culture (IVC) procedure, which is designed to provide a more natural and cost-effective alternative to traditional IVF [5]. - The INVOcell device allows fertilization and early embryo development to occur in vivo, potentially delivering comparable results to traditional methods at a lower cost [5].

As filed with the U.S. Securities and Exchange Commission on October 14, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INVO FERTILITY, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Commission Nevada 001-39701 20-4036208 (I.R.S. Employer Identification Number) 5582 Broadcast Court Sarasota, Florida, 34240 (978) 878- ...

Core Viewpoint - INVO Fertility, Inc. has introduced Platelet-Rich Plasma (PRP) therapy at its Wisconsin Fertility Institute center, enhancing its fertility services and commitment to innovative patient care [1][3]. Group 1: PRP Therapy Overview - PRP therapy utilizes the body's growth factors to promote uterine lining growth and ovarian rejuvenation, potentially improving implantation rates and ovarian response [2]. - This treatment is particularly beneficial for women with specific fertility challenges, such as a thin uterine lining or diminished ovarian reserve, and serves as an alternative to egg donation or surrogacy [2]. Group 2: Company Strategy and Offerings - INVO Fertility focuses on expanding assisted reproductive technology (ART) care through building, acquiring, and operating fertility clinics, including INVO Centers that offer the intravaginal culture (IVC) procedure using the INVOcell medical device [4]. - The INVOcell device allows fertilization and early embryo development to occur in vivo, providing a more natural and affordable experience compared to traditional IVF, with comparable results at a lower cost [4].

Core Viewpoint - INVO Fertility, Inc. is urging shareholders to vote online for the upcoming annual meeting on June 25, 2025, with the Board recommending a "FOR" vote on all proposals to support the company's growth strategies [1][2]. Company Overview - INVO Fertility is focused on expanding assisted reproductive technology (ART) care, primarily through building, acquiring, and operating fertility clinics, including INVO Centers that utilize the INVOcell medical device [5][7]. - The company currently operates two INVO Centers and one IVF clinic in the United States, and it is engaged in the sale and distribution of INVOcell technology to third-party clinics [5][7]. Growth Strategies - The CEO highlighted a robust pipeline of potential transactions for complementary and revenue-generating services and technologies, aiming to leverage the company's public platform for favorable transactions [2]. - The company is focused on acquiring established, profitable fertility clinics and expanding its INVOcell technology to capitalize on favorable market trends and policy developments [2]. Voting Information - Shareholders of record as of May 21, 2025, are entitled to vote at the Annual Meeting, and various voting methods are available, including online, by mail, and by phone [3][6]. - The Annual Meeting will be conducted virtually, allowing shareholders to submit questions and vote online [4].

Core Viewpoint - Cuprina Holdings has completed the construction of an in-vitro fertilization (IVF) media production facility in Singapore, obtaining ISO 13485 certification and a dealer license, aiming to produce 14 SKUs of IVF media products by the fourth quarter of 2026 [1][2][4]. Company Overview - Cuprina Holdings is a biomedical and biotechnology company focused on developing products for chronic wound management, infertility, and cosmeceuticals [8]. - The company has experience in establishing ISO 13485-compliant facilities, which enhances its capability to manage production effectively [7]. Facility and Collaboration - The IVF media production facility was built in collaboration with Ferti-Craft Pte Ltd., a Singapore-based medtech company [3]. - The facility will produce IVF media products containing essential nutrients and materials for in-vitro fertilization [3]. - Ferti-Craft will handle regulatory documentation and logistics for raw materials, contributing expertise in assisted reproductive technology [5]. Regulatory and Market Outlook - The facility aims to secure regulatory approval from the Singapore Health Sciences Authority (HSA) for commercial sale of the IVF media products by late 2026 [4][6]. - The global Assisted Reproductive Technology (ART) market was valued at $34.7 billion in 2023 and is projected to grow at a CAGR of 6.9%, reaching $62.8 billion by 2032 due to increasing infertility rates and acceptance of ART [7].

Core Insights - INVO Fertility, Inc. reported record revenue of $6.5 million for 2024, a 116% increase compared to 2023, driven by the performance of its fertility clinics across the U.S. [4] - The company is refocusing on its core fertility operations following the decision to divest a majority stake in NAYA TX, aiming to capitalize on favorable market trends and increasing public demand for fertility care [4][5] - The U.S. fertility services market is expected to grow due to rising infertility rates and increasing acceptance of assisted reproductive technologies (ART) [7] Q4 2024 Financial Highlights - Revenue for Q4 2024 was $1,685,966, a 22% increase from $1,381,754 in Q4 2023 [6] - Consolidated clinic revenue from the INVO Center in Atlanta and the fertility clinic in Madison increased by 24% to $1,687,300 [6] - Adjusted EBITDA for Q4 2024 was $(450,908), an improvement from $(1.0) million in the prior year [6][14] 2024 Financial Highlights - Total revenue for 2024 reached $6,532,000, up 116% from $3,020,575 in 2023 [6] - Consolidated clinic revenue increased by 125% to $6,450,431 compared to $2,862,574 in 2023 [6] - Net loss for 2024 was $(9.1) million, compared to $(8.0) million in 2023, attributed to the addition of NAYA Therapeutics and merger costs [6] Management Commentary - The CEO highlighted the streamlined operating structure aimed at achieving positive cash flow and the successful expansion into new markets [4] - The company is actively pursuing expansion opportunities in response to declining U.S. fertility rates and rising demand for fertility solutions [4] Market Context - The global fertility services market is projected to grow, driven by rising infertility rates and delayed parenthood [7] - The Centers for Disease Control and Prevention reported a 50% increase in ART-conceived births from 2012 to 2021, with ART now accounting for 2.3% of all births in the U.S. [7]

Core Points - The Wyatt Foundation and The Conceive Fertility Foundation launched a 2025 IVF grant program during National Infertility Awareness Week, offering $15,000 grants to five individuals or couples needing fertility care [1][6] - CooperSurgical is participating for the first time, providing an additional $1,000 for preimplantation genetic testing (PGT) for each grant recipient [2][3] - The program aims to raise awareness about infertility, alleviate financial burdens, and support research for more affordable fertility care options [1][4] Company Overview - The Wyatt Foundation is a 501(c)(3) nonprofit organization focused on helping individuals and couples achieve family-building dreams through assisted reproductive technology (ART) by reducing financial barriers to IVF [8][9] - The Conceive Fertility Foundation, founded by Katy Mimari, aims to support individuals affected by infertility through education and grants, with a portion of Caden Lane's profits funding its mission [4][10] - CooperSurgical, a leader in fertility and women's health for nearly 35 years, is dedicated to providing innovative ART and genomic solutions to enhance fertility care [14][15] Program Details - The IVF grant program covers approximately the cost of one IVF cycle, excluding medication fees, with an additional $1,000 towards PGT with ICSI [5] - Grant recipients can choose their clinic, with those within The Prelude Network receiving a 10% discount on fertility services [5][11] - Applications for the grant are open from April 21, 2025, to June 23, 2025, with recipients announced on July 1, 2025 [6]

As filed with the Securities and Exchange Commission on October 31, 2024 Registration No. 333-281964 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Amendment No. 4 Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NEWGENIVF GROUP LIMITED (Exact name of registrant as specified in its charter) British Virgin Islands 8090 Not Applicable (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Wing Fung Alfred S ...

As filed with the U.S. Securities and Exchange Commission on July 31, 2023 Registration No. 333-273174 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INVO BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) (Primary Standard Industrial Classification Code Number) Nevada 3841 20-4036208 (I.R.S. Employer Identification Number) 5582 Broadcast Court Sarasota, Florida, 34240 (978) 878- ...